PLoS ONE (Jan 2018)

Endotyping of non-allergic, allergic and mixed rhinitis patients using a broad panel of biomarkers in nasal secretions.

  • Christine L Segboer,
  • Wytske J Fokkens,
  • Ingrid Terreehorst,
  • Cornelis M van Drunen

DOI
https://doi.org/10.1371/journal.pone.0200366
Journal volume & issue
Vol. 13, no. 7
p. e0200366

Abstract

Read online

BACKGROUND:Endotyping chronic rhinitis has proven hardest for the subgroup of non-allergic rhinitis (NAR) patients. While IgE-related inflammation is typical for allergic rhinitis (AR), no markers have been found that can be seen to positively identify NAR. A further complication is that AR and NAR might co-exist in patients with mixed rhinitis. As previous studies have considered only a limited number of inflammatory mediators, we wanted to explore whether a wider panel of mediators could help us refine the endotyping in chronic rhinitis patients. OBJECTIVE:To endotype chronic rhinitis, and non-allergic rhinitis in particular, with help of molecular or cellular markers. METHOD:In this study we included 23 NAR patients without allergen sensitizations and with persistent rhinitis symptoms, 22 pollen sensitized rhinitis patients with seasonal symptoms, 21 mixed rhinitis patients with pollen-related symptoms and persistent symptoms outside of the pollen season, and 23 healthy controls without any symptoms. Nasal secretions were collected outside of pollen season and differences between the endotypes were assessed for a broad range of inflammatory mediators and growths factors using a multiplex ELISA. RESULTS:Although we were able to identify two new nasal secretion makers (IL-12 and HGF) that were low in mixed and AR patients versus NAR and healthy controls, the most intriguing outcome is that despite investigating 29 general inflammatory mediators and growth factors no clear profile of non-allergic or mixed rhinitis could be found. CONCLUSION:Classical inflammatory markers are not able to differentiate between non-allergic or mixed rhinitis patients and healthy controls.